[Clinical studies of cefoxitin in the field of abdominal surgery].
Cefoxitin (CFX) was administered to total 25 patients who were admitted to the surgical ward of the hospital. The results of these studies are as follows. 1) Dis susceptibility tests of the 20 strains (many Gram-negative bacilli and 2 strains of anaerobic Bacteroides) isolated from the patients to antibiotic were performed and 17 strains were good susceptibility to CFX. 2) In 9 patients of postoperative infections, 8 patients (including 2 patients with infections due to mixed E. coli and Bacteroides) were good with the clinical efficacy rate of 88.9%. 3) In 16 patients used for prevention of postoperative infections, 15 patients were good with the clinical efficacy rate of 93.8%. 4) No side effects were noted due to CFX. The results of these studies demonstrated that CFX is safe and effective in treatment of infections and for prevention of postoperative infections in the field of gastrosurgery.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D002440:Cefoxitin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D013505:Digestive System Surgical Procedures; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011292:Premedication; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*
D002440:Cefoxitin